LAUSR

Sage Therapeutics Shionogi 90 Sage grants Shionogi exclusive rights in Japan, Taiwan and South Korea to SAGE-217, a next-generation GABAA positive allosteric small-molecule modulator to treat major depressive disorder Skyhawk Therapeutics Celgene 60 Skyhawk grants Celgene an exclusive option to license worldwide rights to RNAtargeting small molecules identified by Skyhawk in up to five neurology programs Translate Bio Sanofi 45 Translate Bio partners with Sanofi's Pasteur division to develop mRNA vaccines against up to five undisclosed pathogens to treat infectious diseases Blueprint Medicines CStone Pharmaceuticals 40 Blueprint Medicines grants CStone Pharmaceuticals exclusive rights to develop and commercialize anticancer small-molecule candidates avapritinib, BLU-667 and BLU-554 in mainland China, including Hong Kong and Macau, and Taiwan Arbutus Biopharma Roivant Sciences 38 Arbutus Biopharma and Roivant Sciences forming JV Genevant Sciences to focus on the discovery, development and commercialization of RNA-based therapeutics delivered via Arbutus's lipid nanoparticle and ligand conjugate technology Oxford BioMedica Axovant Sciences 30 Oxford BioMedica grants Axovant exclusive, worldwide rights to develop and commercialize lentiviral delivered gene therapies OXB-102 and ProSavin to treat Parkinson's disease Zymeworks Daiichi Sankyo 18 Zymeworks grants Daiichi Sankyo rights to its Azymetric and EFECT platforms exploiting modular heterodimeric Fc variants with improved stability andpurity to develop two bispecific antibodies Agios Pharmaceuticals CStone Pharmaceuticals 12 Agios Pharmaceuticals grants CStone Pharmaceuticals exclusive rights to develop and commercialize in China (Mainland, Hong Kong, Macau and Taiwan) the small molecule Tibsovo (ivosidenib), an inhibitor of mutant isocitrate dehydrogenase, as a monotherapy or in combination therapies for cancer